Press release 📈 Stocks 🌍 GLOBAL

Biogen and Eisai Report 76% Lower Alzheimer's Progression in LEADER Study

New real-world findings for LEQEMBI show 76% lower disease progression and consistent safety profiles, with 95% of patients estimated to remain in early-stage Alzheimer's through three years of treatment.

🕐 1 min read

2 assets impacted (Stocks). Net bias: 2 Bullish, 0 Bearish, 0 Neutral. Strongest signal: BIIB ↑ 3/10 (55% confidence).

📊 Affected Assets (2)

BIIB
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

New three-year LEADER real-world data on Leqembi show a 76% lower rate of progression to moderate or severe Alzheimer's disease versus a matched control cohort and 81.1% of patients stable or improved. Supportive real-world evidence strengthens the drug's commercial case for Biogen, though these are retrospective observational results without sales or guidance figures, limiting the price effect.

Catalysts
  • ▲ LEADER analysis of 560 US patients: 76% lower progression to moderate/severe AD (HR 0.24) versus ADNI-weighted control
  • ▲ 77% of monitored patients became amyloid-negative at a median 18.1 months; no ARIA events during subcutaneous maintenance
Risk Factors
  • ▼ Data are retrospective, non-randomized and pre-specified comparisons against an external control cohort, not new trial results
  • ▼ No revenue, prescription or guidance figures accompany the announcement
4523.T
Bullish 🤖 55%
📅 Short-term 🌍 JP · Explicit

Eisai co-markets Leqembi, and the three-year LEADER real-world data show a 76% lower progression rate to moderate or severe Alzheimer's dementia plus low ARIA rates across ~5,000 treated patients. The evidence supports continued adoption of its key drug, but there are no sales or guidance figures, so the effect is modest.

Catalysts
  • ▲ LEADER 560-patient analysis: 76% lower progression to moderate/severe AD (HR 0.24); 87.5% treatment persistence over ~19 months
  • ▲ 64 patients on weekly subcutaneous maintenance all remained on therapy with no ARIA events during the SC maintenance period
Risk Factors
  • ▼ Retrospective chart-review data without a randomized head-to-head comparison
  • ▼ Announcement contains no revenue, prescription uptake or financial guidance figures

🧭 Full analysis of these assets

🎯 Key Takeaways

  • LEADER study participants showed a 76% lower rate of progression to moderate or severe Alzheimer's dementia compared to a matched control cohort.
  • 81.1% of 546 assessed patients remained stable or improved after an average of 18 months of treatment.
  • A meta-analysis of approximately 5,000 patients across six countries reported a pooled total ARIA rate of 12.4%, lower than the 21.5% seen in the Clarity AD trial.
  • 95.0% of the 560 patients in the LEADER study were estimated to remain in early-stage Alzheimer's disease through 36 months of treatment.

📝 Executive Summary

Biogen and Eisai presented three-year real-world data from the LEADER study at the CTAD conference, showing a 76% lower rate of progression to moderate or severe Alzheimer's disease. The analysis of 560 U.S. patients also indicated that 81.1% of participants remained stable or improved after approximately 18 months of treatment with LEQEMBI.

❓ FAQ

BIIB · What did the new Leqembi data show?

In the 560-patient LEADER study, patients had a 76% lower rate of progressing to moderate or severe Alzheimer's dementia versus a matched control group, 81.1% were stable or improved after about 18 months, and 95.0% were estimated to remain in early-stage disease through three years of treatment.

BIIB · Is this new data a big positive for Biogen?

It is supportive: real-world results back up the clinical trial benefits and show low ARIA rates in routine practice. However, it is observational data presented at a conference without sales numbers or guidance changes, so the stock impact is likely modest.

4523.T · What did the new Leqembi data show?

In the 560-patient LEADER study, patients had a 76% lower rate of progressing to moderate or severe Alzheimer's dementia versus a matched control group, 81.1% were stable or improved after about 18 months, and 95.0% were estimated to remain in early-stage disease through three years of treatment.

4523.T · Is this new data a big positive for Eisai?

It is supportive: real-world results back up the clinical trial benefits and show low ARIA rates in routine practice. However, it is observational data presented at a conference without sales numbers or guidance changes, so the stock impact is likely modest.